<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:department>Pharmacy</gtr:department><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0FD843B2-6A4E-4C7B-BE09-7AC267846A35"><gtr:id>0FD843B2-6A4E-4C7B-BE09-7AC267846A35</gtr:id><gtr:firstName>Wafa</gtr:firstName><gtr:surname>Al-Jamal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=EP%2FM008657%2F1"><gtr:id>47902AD7-F553-4161-A7E0-948C75D5BB11</gtr:id><gtr:title>Engineering Multi-functional Nanomaterials to Treat Metastatic Cancer</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/M008657/1</gtr:grantReference><gtr:abstractText>Prostate cancer is the most common type of cancer and the second most common cause of death in men in the UK. Cancer metastasis (cancer cells spread outside the primary tumour) is the most serious complication of prostate cancer, with median patient survival of 12-18 months with current available chemotherapeutics. Chemotherapy is an approach which utilises anti-cancer drugs for killing tumour cells however it is associated with undesirable side effects due to its acting on normal healthy cells. Following systemic administration, cytotoxic drugs are eliminated rapidly from the blood stream which results in poor drug accumulation at metastatic cancer lesions. To overcome these shortcomings, drugs have been encapsulated into ultra-small objects called &amp;quot;nanocarriers&amp;quot;. Liposomes are one example of these nanocarriers, made of natural lipid composition thus considered as the safest nanocarrier systems developed so far. Encapsulation of drugs into liposomes prolongs their residency time in the blood by decreasing their renal and hepatic clearance. In addition, drug-loaded nanocarriers will utilise the tumour leaky vasculature, known as enhanced permeation and retention (EPR) effect, to improve drug delivery to cancer cells. However, the poor release of the drug from such nanocarriers is considered the main challenge in cancer drug delivery. In this proposal we describe the development of targeted delivery systems that recognise prostate cancer cells, and efficiently release the encapsulated chemotherapeutics in response to an externally applied magnetic field. Such an approach aims to increase drug accumulation at the tumour tissues, and reduce undesirable systemic side effects. The targeting ligand was chosen to recognise only prostate cancer cells as this targeting moiety recognises specific proteins (called PSMA) only expressed on this cell type thus sparing healthy tissues. To overcome the poor release of the drug, temperature-sensitive liposomes (TSL) will be formulated so that they &amp;quot;break down&amp;quot; and release the drug only at temperatures higher than the body temperature (i.e.42C). The temperature-sensitive liposomes will be developed by incorporating magnetic iron oxide nanoparticles inside the liposomes besides the anticancer drug. The magnetic nanoparticles will heat when exposed to a &amp;quot;safe&amp;quot; alternating magnetic field so that the drug can be released from the TSL. At the same time the magnetic nanoparticles will act as &amp;quot;imaging agents&amp;quot; so their accumulation in the tumour will be visualized by Magnetic Resonance Imaging (MRI). This proposal aims to translate our innovative delivery system as a potential therapy for metastatic prostate cancer. It is anticipated that safer and more effective targeted nanocarriers will emerge to treat metastatic prostate cancer so that chemotherapy side effects are hugely reduced.</gtr:abstractText><gtr:potentialImpactText>This project will have an impact in academia and industry and will address all those interested in nanomedicine, in particular for cancer therapy. Such a collaborative project promises to bring about a long-term benefit to the development of UK science and its clinical translation. It is relevant to pharmaceutical and medical companies interested in developing novel therapeutic approaches to treat cancer (specifically metastatic cancers). The research aims to improve and expand on prostate cancer therapy options to prolong patient survival, and enhance the quality of life for UK and European citizens. It has the potential to contribute to knowledge transfer among the different national collaborators who are experts in their field. The development of nanopharmaceuticals is an emerging multidisciplinary area and research within a multidisciplinary team is mandatory for progress in the field. It is expected that a number of additional national, EU or independently funded collaborative projects will follow the developments achieved by this project. After showing a proof-of-concept how our multifunctional nanoparticles can be used to target and treat metastatic prostate cancer, future funding for further clinical testing and commercialisation of the novel temperature-sensitive nanoparticle-liposome hybrids will be sought along with an industrial partner.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-07-21</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2015-05-18</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99870</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Attending prostate cancer reception at Whitehall, London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5054BAC6-4B8E-4D80-9179-5C7B11CAD57C</gtr:id><gtr:impact>Dr Wafa Al-Jamal, Prostate Cancer Research Fellow at the School of Pharmacy, and Ms Sara Pereira were invited to The Prostate Cancer Reception held at Admiralty House, Whitehall London. The reception was hosted by The Deputy Prime Minister, Nick Clegg, and Norman Lamb MP. The reception invited prostate cancer researchers, clinicians, and representatives from the Movember organisation to support prostate cancer patients and to increase public awareness of prostate cancer.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.uea.ac.uk/pharmacy/news-and-events/-/asset_publisher/w7O8j7rUDTtg/blog/dr-wafa-al-jamal-attends-prostate-cancer-reception-at-whitehall-london?inheritRedirect=false&amp;redirect=https%3A%2F%2Fwww.uea.ac.uk%3A443%2Fpharmacy%2Fnews-and-events%3Fp_p_i</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer UK Research Network Day-London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1E193C04-D962-45F2-935B-119DE3341B5A</gtr:id><gtr:impact>The meeting was organised by the PCUK (23-Oct-2015) to enhance the interaction between the researchers, health care professionals, prostate cancer patients and charity donors and supporters. The event aimed to publicise the types of research funded by PCUK as well as to encourage the audience to participate in funding raising activities to help prostate cancer research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://prostatecanceruk.org/research/for-researchers/making-progress-research-network-day</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosetrees Trust studentship Scheme</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:fundingRef>A1108</gtr:fundingRef><gtr:id>7ABC733D-2CE6-40AE-8169-7E54AB916B50</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Royal Society</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:fundingRef>R22677</gtr:fundingRef><gtr:id>739B2BA7-0414-4BBD-878F-E6449C953BC1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Engineering and Physical Sciences Research Council EPSRC</gtr:department><gtr:description>EPSRC First Grant Scheme</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:fundingRef>EP/M008657/1</gtr:fundingRef><gtr:id>2F381406-5FDA-44DA-AB9D-F3A2F3C5B50E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PCUK Research Advisory Committee Meeting</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1E21378B-D4DD-4047-8B57-086A0D1F47A4</gtr:id><gtr:impact>NA</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C642A126-EA62-47F6-97FF-84B32ECF4B6A"><gtr:id>C642A126-EA62-47F6-97FF-84B32ECF4B6A</gtr:id><gtr:title>In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with ?d T cell immunotherapy in mice.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fa5447385c796a5ef8e33404f06df375"><gtr:id>fa5447385c796a5ef8e33404f06df375</gtr:id><gtr:otherNames>Hodgins NO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7D9A7E7E-9F88-481C-953F-22BC00DB94DB"><gtr:id>7D9A7E7E-9F88-481C-953F-22BC00DB94DB</gtr:id><gtr:title>Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fdbc5d5447e5d5f6408c86864d743189"><gtr:id>fdbc5d5447e5d5f6408c86864d743189</gtr:id><gtr:otherNames>Pereira S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/M008657/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B30DC286-3309-48E2-A15D-BDF547057A33</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Drug Formulation &amp; Delivery</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>063026C5-CD0B-48AB-82F3-6359499A95D4</gtr:id><gtr:percentage>60</gtr:percentage><gtr:text>Materials Synthesis &amp; Growth</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>